Collaboration and License Agreements (Tables)

3 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Revenue

The following table provides a summary of revenue recognized:

	Three Months Ended December 31,
	2023		2022
	(in thousands)
GSK	$	2,685	$	(677)
Horizon	—		21,667
Takeda	866		16,312
Janssen	—		244
Amgen	—		25,000
Total	$	3,551	$	62,546

Schedule of Receivables and Contract Liabilities

The following table summarizes the balance of receivables and contract liabilities related to the Company’s collaboration and license agreements:

	December 31, 2023		September 30, 2023
	(in thousands)
Receivables included in accounts receivable	$	—	$	—
Contract liabilities included in deferred revenue	$	—	$	866